Repligen (NASDAQ:RGEN) Price Target Cut to $195.00 by Analysts at UBS Group

Repligen (NASDAQ:RGEN) had its target price lowered by research analysts at UBS Group from $200.00 to $195.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. UBS Group’s price objective would suggest a potential upside of 47.54% from the company’s previous close.

Other equities analysts have also issued research reports about the company. Wall Street Zen raised Repligen from a “hold” rating to a “buy” rating in a research report on Saturday, February 7th. Jefferies Financial Group set a $160.00 price target on Repligen and gave the stock a “hold” rating in a research note on Tuesday, October 28th. Barclays reduced their price objective on Repligen from $200.00 to $175.00 and set an “overweight” rating for the company in a research report on Wednesday. Weiss Ratings raised Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, February 17th. Finally, Wells Fargo & Company lowered their price objective on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $174.58.

Repligen Stock Down 1.9%

NASDAQ:RGEN traded down $2.51 on Wednesday, reaching $132.17. 893,531 shares of the stock traded hands, compared to its average volume of 769,279. The company has a current ratio of 8.36, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $7.44 billion, a price-to-earnings ratio of 6,606.20, a PEG ratio of 2.47 and a beta of 1.13. Repligen has a 12 month low of $102.96 and a 12 month high of $175.77. The company’s fifty day simple moving average is $155.83 and its 200 day simple moving average is $146.87.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $197.91 million for the quarter, compared to analysts’ expectations of $192.23 million. Repligen had a net margin of 0.25% and a return on equity of 4.66%. The business’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.44 earnings per share. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities analysts predict that Repligen will post 1.72 EPS for the current fiscal year.

Insider Buying and Selling at Repligen

In other Repligen news, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the transaction, the director directly owned 91,821 shares of the company’s stock, valued at $14,783,181. This trade represents a 0.30% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

Several institutional investors and hedge funds have recently made changes to their positions in the business. Bayforest Capital Ltd purchased a new position in Repligen during the 4th quarter worth $32,000. Rachor Investment Advisory Services LLC bought a new position in shares of Repligen during the 4th quarter worth $33,000. Measured Wealth Private Client Group LLC purchased a new position in shares of Repligen during the third quarter valued at $29,000. Los Angeles Capital Management LLC bought a new stake in shares of Repligen in the fourth quarter valued at about $36,000. Finally, Hantz Financial Services Inc. raised its holdings in shares of Repligen by 2,663.6% in the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 293 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Key Headlines Impacting Repligen

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Q4 beat: Repligen reported $0.49 EPS vs. $0.44 expected and $197.9M revenue (+18% Y/Y), with management highlighting solid organic growth and improving margins. Article Title
• Neutral Sentiment: Mixed analyst views on valuation vs. growth: TD Cowen maintained a Buy and $200 PT, signaling continued conviction in long-term upside. Article Title
• Neutral Sentiment: Canaccord Genuity reiterated a Hold and $165 PT, noting solid execution but limited near-term upside at current valuation. Article Title
• Negative Sentiment: Conservative FY2026 guidance: Repligen set EPS guidance of $1.93–$2.01 and revenue $810–$840M, below consensus — investors typically punish guidance that implies slower near‑term growth. Article Title
• Negative Sentiment: Barclays trimmed its price target from $200 to $175 (keeps an Overweight rating), reducing upside expectations and likely contributing to selling pressure. Article Title
• Negative Sentiment: Wells Fargo lowered its target from $190 to $180 while maintaining Overweight, another near‑term negative signal for sentiment. Article Title

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.